Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AORT
Upturn stock ratingUpturn stock rating

Artivion Inc (AORT)

Upturn stock ratingUpturn stock rating
$32.56
Last Close (24-hour delay)
Profit since last BUY14.13%
upturn advisory
Consider higher Upturn Star rating
BUY since 43 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/10/2025: AORT (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $32.71

1 Year Target Price $32.71

Analysts Price Target For last 52 week
$32.71 Target price
52w Low $21.97
Current$32.56
52w High $32.94

Analysis of Past Performance

Type Stock
Historic Profit 41.49%
Avg. Invested days 46
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/10/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.51B USD
Price to earnings Ratio -
1Y Target Price 32.71
Price to earnings Ratio -
1Y Target Price 32.71
Volume (30-day avg) 6
Beta 1.62
52 Weeks Range 21.97 - 32.94
Updated Date 07/10/2025
52 Weeks Range 21.97 - 32.94
Updated Date 07/10/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.51

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -5.49%
Operating Margin (TTM) -0.69%

Management Effectiveness

Return on Assets (TTM) 1.54%
Return on Equity (TTM) -7.26%

Valuation

Trailing PE -
Forward PE 102.04
Enterprise Value 1836909793
Price to Sales(TTM) 3.88
Enterprise Value 1836909793
Price to Sales(TTM) 3.88
Enterprise Value to Revenue 4.71
Enterprise Value to EBITDA 52.09
Shares Outstanding 47037100
Shares Floating 37726629
Shares Outstanding 47037100
Shares Floating 37726629
Percent Insiders 5.01
Percent Institutions 97.31

ai summary icon Upturn AI SWOT

Artivion Inc

stock logo

Company Overview

overview logo History and Background

Artivion, Inc., formerly CryoLife, Inc., was founded in 1984. Initially focused on cryopreservation of human tissues, it expanded to develop and manufacture medical devices for cardiac and vascular surgeries. Significant milestones include FDA approvals for key products and acquisitions to broaden its product portfolio.

business area logo Core Business Areas

  • Aortic: Develops, manufactures and distributes devices and implantable tissues used to repair or replace diseased or damaged aortic vessels. Products include aortic valves, aortic conduits, and stent grafts.
  • Surgical Sealants: Offers BioGlue Surgical Adhesive, a surgical sealant used in various surgical procedures to achieve hemostasis and tissue sealing.
  • Perfusion: Provides a range of perfusion products used during open-heart surgery, including oxygenators, blood filters, and other related devices.
  • Cardiac Preservation: The company offers preservation services to preserve cardiovascular tissue.

leadership logo Leadership and Structure

Artivion is led by President and CEO Pat Mackin. The company has a board of directors overseeing its operations. The organizational structure includes functional departments such as R&D, manufacturing, sales and marketing, and finance.

Top Products and Market Share

overview logo Key Offerings

  • BioGlue Surgical Adhesive: A surgical sealant used in cardiovascular and general surgeries. Competitors include Baxter International (Tisseel), Johnson & Johnson (Evicel), and Medtronic (DuraSeal). Revenue from this product is significant, constituting a substantial portion of the surgical sealants segment revenue. Market share data fluctuates, but BioGlue holds a competitive position. Market share is unavailable.
  • EACT (acellularized pulmonary homograft): Cryopreserved human tissues used for aortic and pulmonary valve replacement. Competitors include Medtronic, Edwards Lifesciences, and Abbott. Market share is unavailable.
  • Aortic Stent Grafts: Used in endovascular repair of aortic aneurysms. Competitors include Medtronic, W. L. Gore & Associates, and Cook Medical. Market share is unavailable.

Market Dynamics

industry overview logo Industry Overview

The medical device industry is experiencing growth driven by an aging population, increasing prevalence of cardiovascular diseases, and technological advancements. Regulatory approvals and reimbursement policies significantly impact market access.

Positioning

Artivion is a player in the cardiovascular and surgical medical device market, with strengths in tissue-based products and surgical sealants. Its competitive advantage lies in its BioGlue product and established relationships with surgeons.

Total Addressable Market (TAM)

The global cardiovascular device market is estimated to be over $50 billion and growing. Artivion is positioned to capture a portion of this TAM through its product portfolio and strategic initiatives. TAM specifically for Artivion's product lines is unavailable.

Upturn SWOT Analysis

Strengths

  • Proprietary products like BioGlue
  • Established relationships with surgeons
  • Strong brand reputation in certain product lines
  • Focus on innovation in cardiovascular surgery
  • Diverse product portfolio

Weaknesses

  • Dependence on regulatory approvals
  • Competition from larger medical device companies
  • Potential product liability risks
  • Manufacturing complexities associated with tissue-based products

Opportunities

  • Expanding into new geographic markets
  • Developing new applications for existing products
  • Acquiring complementary technologies or products
  • Capitalizing on the growing demand for minimally invasive surgical procedures

Threats

  • Changes in reimbursement policies
  • Increased competition from new entrants
  • Product recalls or safety concerns
  • Economic downturn affecting hospital budgets

Competitors and Market Share

competitor logo Key Competitors

  • Edwards Lifesciences (EW)
  • Medtronic (MDT)
  • Baxter International (BAX)
  • Johnson & Johnson (JNJ)

Competitive Landscape

Artivion faces competition from larger, more established medical device companies. Artivion's advantages lie in its specialized product offerings and focus on specific surgical procedures. Disadvantages include its smaller size and limited resources compared to its competitors.

Major Acquisitions

Jotec AG

  • Year: 2017
  • Acquisition Price (USD millions): 276
  • Strategic Rationale: Expanded Artivion's presence in the European market and added a portfolio of aortic and peripheral vascular products.

Growth Trajectory and Initiatives

Historical Growth: Artivion's growth has been driven by organic sales growth and acquisitions. The company has focused on expanding its product portfolio and geographic reach.

Future Projections: Future growth projections depend on analyst estimates and company guidance. These projections would be based on factors such as new product launches, market trends, and competitive landscape.

Recent Initiatives: Recent strategic initiatives include acquisitions to expand product offerings and investments in R&D to develop innovative medical devices.

Summary

Artivion is a player in the cardiovascular and surgical medical device market with a focus on aortic and surgical sealants. Strengths in niche products are being weighed against competition from larger companies. The company's focus on strategic acquisitions is helping to expand the company. Artivion needs to navigate regulatory landscape and competitive pressures carefully, while the company needs to innovate its product offering for continued growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Market research reports
  • Analyst reports

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Artivion Inc

Exchange NYSE
Headquaters Kennesaw, GA, United States
IPO Launch date 1993-02-12
Chairman, President & CEO Mr. James Patrick Mackin
Sector Healthcare
Industry Medical Devices
Full time employees 1600
Full time employees 1600

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.